Last reviewed · How we verify
Neuroleptanalgesia
Neuroleptanalgesia is a Small molecule drug developed by GCS Ramsay Santé pour l'Enseignement et la Recherche. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Neuroleptanalgesia |
|---|---|
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Benefit of Hypnoanalgesia Versus Neuroleptanalgesia During Hand Surgery (NA)
- Minimally Invasive Superficial Venous Insufficiency Surgery and Digital Sedation (NA)
- Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuroleptanalgesia CI brief — competitive landscape report
- Neuroleptanalgesia updates RSS · CI watch RSS
- GCS Ramsay Santé pour l'Enseignement et la Recherche portfolio CI
Frequently asked questions about Neuroleptanalgesia
What is Neuroleptanalgesia?
Who makes Neuroleptanalgesia?
What development phase is Neuroleptanalgesia in?
Related
- Manufacturer: GCS Ramsay Santé pour l'Enseignement et la Recherche — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing